| Miss Tari Lynn Justis, APN | |
|
645 N Arlington Ave, Reno, NV 89503-4505 | |
| (775) 329-6241 | |
| (775) 324-6549 |
| Full Name | Miss Tari Lynn Justis |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Women's Health |
| Location | 645 N Arlington Ave, Reno, Nevada |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801083209 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SW0102X | Clinical Nurse Specialist - Women's Health | 00210 (Nevada) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Tari Lynn Justis, APN 645 N Arlington Ave, Reno, NV 89503-4505 Ph: (775) 329-6241 | Miss Tari Lynn Justis, APN 645 N Arlington Ave, Reno, NV 89503-4505 Ph: (775) 329-6241 |
News Archive
Some hospitals are using a "customer management system" to "market to patients and physicians the same way supermarkets do - by sending information they think a customer needs or wants based on their history," American Medical News reports. "The use of CRM software by the health industry is aided by the increasing automation of data ranging from physician referrals to electronic medical records.
NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.
› Verified 3 days ago
Renee Hinojosa, APRN, ACNS-BC, MSN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 9393 Gateway Dr, Reno, NV 89521 Phone: 775-787-8300 | |
Mrs. Annette Elaine Rothman, CPNP, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 338 California Ave, Reno, NV 89509 Phone: 775-239-1050 | |
Laurie D Mcginley, APN Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 75 Pringle Way, Suite 1002, Reno, NV 89502 Phone: 775-323-7500 Fax: 775-789-9208 | |
Linda Diane Smith, APN Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 540 W Plumb Ln, Suite 2a, Reno, NV 89509 Phone: 775-348-1811 Fax: 775-348-7139 | |
Mrs. Christine Carla Nicks, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1000 Locust St, Reno, NV 89502 Phone: 775-328-1747 | |
Jane Whipple, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1000 Locust St, Reno, NV 89502 Phone: 775-786-7200 |